Travere Therapeutics appoints Sandra Calvin as Chief Accounting Officer effective Sept 15, 2021

Travere Therapeutics, Inc.

Sandra Calvin, 56, appointed Vice President, Corporate Controller and Chief Accounting Officer.
Calvin has served as VP, Corporate Controller since April 2018; joined the company in 2014.
Laura Clague remains CFO and principal financial officer; Calvin assumes principal accounting officer duties.
Calvin is a CPA (inactive) with prior roles at Amylin Pharmaceuticals and Vical Incorporated.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sandra Calvin

Vice President, Corporate Controller and Chief Accounting Officer

TVTX · Travere Therapeutics, Inc.

Effective: 2021-09-15
Filed: September 17, 2021, 7:59 PM ET

On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved the appointment of Sandra Calvin as the Company’s principal accounting officer, effective September 15, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra Calvin was appointed as Vice President, Corporate Controller and Chief Accounting Officer at Travere Therapeutics, Inc..

Action: appointed
Role: Vice President, Corporate Controller and Chief Accounting Officer

Exact text from the filing

On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved the appointment of Sandra Calvin as the Company’s principal accounting officer, effective September 15, 2021.

View on SEC.gov

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-21-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.